

TOPICS of interest

- Understanding tumor heterogeneity and resistance (innate and acquired resistance to targeted agents or resistance to chemotherapy): including single cell analyses of treatment resistant tumors, studies with persistent tumor cells and studies of minimal residual disease
- Identification of driver oncogenic & immune pathways and effects of pharmacological modulation in preclinical models, particularly explants, representative of Asian cancers
- New disease models: including studies with immunocompetent mouse models, new hematological cancer models, preclinical models of CDK4/6 and PARP resistance and PDXs in 1st line Osimertinib resistance
- New combinations with novel agents,
- Translational science studies using CT-DNA
- Understanding key metabolic pathways and dependencies in Asian cancers* (HCC, GC would be of particular interest)

